Eli Lilly | Netto Inntekt



Net Income Endring Dato
AbbVie USD -22000000 1.58B 2024-12
Abbott USD 9.23B 7.58B 2024-12
ALKERMES USD 367.07M 274.69M 2024-12
Amgen USD 627M 2.2B 2024-12
AstraZeneca USD 1.5B 71M 2024-12
Baxter International USD -512000000 652M 2024-12
Biogen USD 266.7M 121.8M 2024-12
Bristol-Myers Squibb USD 72M 1.14B 2024-12
Drreddys Laboratories INR 14.13B 1.58B 2024-12
Eli Lilly USD 4.41B 3.44B 2024-12
Gilead Sciences USD 1.78B 529M 2024-12
GlaxoSmithKline GBP 414M 472M 2024-12
Glaxosmithkline GBP 414M 472M 2024-12
Indivior 4M 111M 2024-09
J&J USD 3.43B 737M 2024-12
Medtronic USD 1.29B 25M 2025-01
Merck USD 3.74B 586M 2024-12
Neurocrine Biosciences USD 103.1M 26.7M 2024-12
Novartis USD 2.82B 371M 2024-12
Novartis USD 2.82B 371M 2024-12
Novo Nordisk 27.3B 7.25B 2024-09
Perrigo USD -44500000 23.5M 2024-12
Pfizer USD 410M 4.06B 2024-12
Prestige Brands USD 61.03M 6.65M 2024-12
Regeneron Pharmaceuticals USD 917.7M 422.9M 2024-12
Roche Holding CHF 1.01B 2.12B 2024-12
Sanofi EUR 2.82B 1.7B 2024-09
Sanofi EUR 2.82B 1.7B 2024-09
United Therapeutics USD 301.3M 7.8M 2024-12
Zoetis USD 581M 101M 2024-12



Eli Lilly Netto Inntekt - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Mar 2025.